Ardelyx's second quarter was, on the reported line, the cleanest of the company's life. Total product revenue reached $118.1 million, a 31% increase over the year-ago quarter; on the deck, management called it "the largest quarterly revenue in our Company's history." The same release cut full-year IBSRELA guidance to $350–$370 million from a prior $410–$430 million, withdrew XPHOZAH's long-term target outright, and pointed at a payor-side step-up in utilization management on IBSRELA that compressed the second quarter. The market's read was a verdict: shares closed the day at $4.87, fell to $3.91 a week later - a 52-week low - taking roughly a third of market value off the print in five sessions and giving Ardelyx a market capitalization near $975 million. The headline earnings beat was a mirage; the guidance reset is the report. This one is about whether the cut is the new floor or the start of a curve the market is right to keep bending.
The quarter's mechanics are concrete. IBSRELA delivered $86.2 million, up 33%, with management citing higher refills and total prescriptions and "the highest demand quarter to date" - even as the payor side pushed back, and the company acknowledged Q2 revenue was "below our expectations." XPHOZAH added $31.9 million, up 27%, on a stronger writer count and improved net price. The H1 tally was $211.5 million in product revenue (+34% year over year), with a net loss of $54.3 million, or $(0.22) per share, against operating cash use of $38.6 million. The balance sheet at quarter-end held $281.8 million in cash, cash equivalents and short-term investments, against $251.8 million of long-term debt - the latter up from $202.8 million at year-end 2025 after a fourth draw on the SLR term loan and a $50 million draw at quarter-end.
Two structural items frame the story and the path. The company refinanced its SLR loan in April, extending the maturity to July 1, 2030 at a 4.55% spread over one-month SOFR (or a 3.50% floor), and re-confirmed $50 million of incremental tranche still available to draw through year-end. The same day as the earnings release, the D.C. Circuit affirmed the dismissal of Ardelyx's lawsuit against CMS over XPHOZAH's inclusion in the ESRD Prospective Payment System - closing a legal channel that had been the company's only leverage to recover a Medicare Part D coverage channel, and leaving the March 27, 2026 CMS operational guidance as the binding rule: ESRD facilities furnish XPHOZAH under the bundled payment regardless of manufacturer preference. The Phase 3 ACCEL program in chronic idiopathic constipation (CIC) continues enrolling, with topline guided to the second half of 2027; the next-generation NHE3 inhibitor RDX10531 remains in IND-enabling studies.
The investment case at $3.91 rests on three load-bearing questions. The first is whether the IBSRELA payor friction is a discrete 2026 event the company can route around (management named "actively addressing" the issue, with an additional disease-awareness spend) or the beginning of a structural margin compression as pharmacy-benefit managers tighten. The second is whether XPHOZAH's bundled-payment ceiling becomes the new flat line for that asset - XPHOZAH long-term guidance was pulled, the legal channel is closed, and the drug has now gone three consecutive quarters at a sub-30% growth rate. The third is whether the pipeline can carry the franchise after the two commercial products are fully priced-in: the ACCEL readout is 12-15 months away, RDX10531 is preclinical, and there is no other late-stage clinical asset. The thesis is a H1 2026 inflection or a 2026 reset; the year-end report reads it.